title: ÐÐ½ÐµÑÐµÐ½Ð¸Ðµ ÐºÐ¾Ð½ÑÐµÑÐ²Ð°ÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÐ° Ð2Ðµ Ð² Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð½ÑÐ¹ ÑÐ°Ð¹Ñ Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð° Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° Ð Ð´Ð»Ñ ÑÐ¾Ð·Ð´Ð°Ð½Ð¸Ñ Ð¿ÑÐ¾ÑÐ¾ÑÐ¸Ð¿Ð° ÑÐ½Ð¸Ð²ÐµÑÑÐ°Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½Ð¾Ð¹ Ð²Ð°ÐºÑÐ¸Ð½Ñ
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Insertion of the conservative M2e fragment into the antigenic hemagglutinin site of the influenza A virus for creating a prototype of a universal influenza vaccine
Creators: name: ÐÐµÑÐºÑÑÑÐµÐ², ÐÐ»ÐµÐºÑÐ°Ð½Ð´Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: Ð²Ð¸ÑÑÑ Ð³ÑÐ¸Ð¿Ð¿Ð°
Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½
ÑÐ½Ð¸Ð²ÐµÑÑÐ°Ð»ÑÐ½Ð°Ñ Ð²Ð°ÐºÑÐ¸Ð½Ð°
ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÐ¹ ÑÑÐ°Ð¼Ð¼
Ð²Ð½ÐµÐºÐ»ÐµÑÐ¾ÑÐ½ÑÐ¹ ÑÐ¿Ð¸ÑÐ¾Ð¿ Ð2Ðµ
Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð½ÑÐ¹ ÑÐ°Ð¹Ñ Sb
Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð³ÐµÐ½Ð½Ð¾ÑÑÑ
Ð¼ÐµÑÐ¾Ð´Ñ Ð¾Ð±ÑÐ°ÑÐ½Ð¾Ð¹ Ð³ÐµÐ½ÐµÑÐ¸ÐºÐ¸
Ð¶Ð¸Ð²Ð°Ñ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½Ð°Ñ Ð²Ð°ÐºÑÐ¸Ð½Ð°
influenza virus
hemagglutinin
universal vaccine
recombinant strain
extracellular epitope M2
antigenic site Sb
immunogenicity
reverse genetics methods
live influenza vaccine

description: Ð¦Ð¸ÑÐºÑÐ»ÑÑÐ¸Ñ Ð²Ð¸ÑÑÑÐ¾Ð² Ð³ÑÐ¸Ð¿Ð¿Ð° ÑÑÐµÐ´Ð¸ Ð¶Ð¸Ð²Ð¾ÑÐ½ÑÑ Ð¸ Ð»ÑÐ´ÐµÐ¹ Ð´Ð¾ ÑÐ¸Ñ Ð¿Ð¾Ñ ÑÐ²Ð»ÑÐµÑÑÑ Ð·Ð½Ð°ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾Ð¹ Ð¿ÑÐ¾Ð±Ð»ÐµÐ¼Ð¾Ð¹ Ð·Ð´ÑÐ°Ð²Ð¾Ð¾ÑÑÐ°Ð½ÐµÐ½Ð¸Ñ. ÐÑÐ½Ð¾Ð²Ð½ÑÐ¼ ÑÑÐµÐ´ÑÑÐ²Ð¾Ð¼ Ð±Ð¾ÑÑÐ±Ñ Ñ Ð´Ð°Ð½Ð½ÑÐ¼ ÑÐ¸Ð¿Ð¾Ð¼ Ð²Ð¸ÑÑÑÐ¾Ð² ÑÐ²Ð»ÑÐµÑÑÑ Ð²Ð°ÐºÑÐ¸Ð½Ð°ÑÐ¸Ñ. ÐÐ¾ ÑÐµÐºÑÑÐ¸Ðµ Ð²Ð°ÐºÑÐ¸Ð½Ñ Ð·Ð°ÑÐ°ÑÑÑÑ Ð¾Ð±Ð»Ð°Ð´Ð°ÑÑ Ð½Ð¸Ð·ÐºÐ¾Ð¹ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑÑ. ÐÐ¾ÑÑÐ¾Ð¼Ñ Ð¿Ð¾ Ð²ÑÐµÐ¼Ñ Ð¼Ð¸ÑÑ Ð²ÐµÐ´ÑÑÑÑ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¸ Ð²Ð°ÐºÑÐ¸Ð½, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð±Ñ Ð¸Ð¼ÐµÐ»Ð¸ Ð±Ð¾Ð»ÐµÐµ ÑÐ¸ÑÐ¾ÐºÐ¸Ð¹ Ð¸ Ð¿ÑÐ¾Ð´Ð¾Ð»Ð¶Ð¸ÑÐµÐ»ÑÐ½ÑÐ¹ ÑÐ¿ÐµÐºÑÑ Ð´ÐµÐ¹ÑÑÐ²Ð¸Ñ. ÐÐ´Ð½Ð¸Ð¼ Ð¸Ð· Ð¿Ð¾Ð´ÑÐ¾Ð´Ð¾Ð² Ð¿Ð¾ ÑÐ¾Ð·Ð´Ð°Ð½Ð¸Ñ ÑÐ°ÐºÐ¸Ñ Ð²Ð°ÐºÑÐ¸Ð½ ÑÐ²Ð»ÑÐµÑÑÑ Ð¸Ð½Ð´ÑÐºÑÐ¸Ñ ÑÑÐ¸Ð»ÐµÐ½Ð½Ð¾Ð³Ð¾ Ð¸Ð¼Ð¼ÑÐ½Ð½Ð¾Ð³Ð¾ Ð¾ÑÐ²ÐµÑÐ° Ðº ÐºÐ¾Ð½ÑÐµÑÐ²Ð°ÑÐ¸Ð²Ð½ÑÐ¼ ÑÑÐ°ÑÑÐºÐ°Ð¼ Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° ÑÐ°ÐºÐ¸Ð¼, ÐºÐ°Ðº Ð²Ð½ÐµÐºÐ»ÐµÑÐ¾ÑÐ½ÑÐ¹ Ð´Ð¾Ð¼ÐµÐ½ Ð¼ÐµÐ¼Ð±ÑÐ°Ð½Ð½Ð¾Ð³Ð¾ Ð±ÐµÐ»ÐºÐ° Ð2 (Ð2Ðµ). Ð Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÐµ Ð¿ÑÐ¾Ð²Ð¾Ð´Ð¸Ð»Ð¾ÑÑ Ð²ÑÑÑÐ°Ð¸Ð²Ð°Ð½Ð¸Ðµ ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÐ° M2e Ð² ÑÐ¿Ð¸ÑÐ¾Ð¿ Sb Ð³Ð»Ð¾Ð±ÑÐ»ÑÑÐ½Ð¾Ð³Ð¾ Ð´Ð¾Ð¼ÐµÐ½Ð° Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÐ½Ð¾Ð³Ð¾ Ð±ÐµÐ»ÐºÐ° Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð° (HA) Ð¼ÐµÑÐ¾Ð´Ð°Ð¼Ð¸ Ð¾Ð±ÑÐ°ÑÐ½Ð¾Ð¹ Ð³ÐµÐ½ÐµÑÐ¸ÐºÐ¸. Ð Ð´Ð°Ð»ÐµÐµ Ð±ÑÐ» Ð¿Ð¾Ð»ÑÑÐµÐ½ ÑÐ¾Ð¾ÑÐ²ÐµÑÑÑÐ²ÑÑÑÐ¸Ð¹ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÐ¹ Ð²Ð°ÐºÑÐ¸Ð½Ð½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ Ð´Ð¾Ð½Ð¾ÑÐ° Ð°ÑÑÐµÐ½ÑÐ°ÑÐ¸Ð¸ Ð/ÐÐµÐ½Ð¸Ð½Ð³ÑÐ°Ð´/134/17/57. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ ÑÐµÐ¿Ð»Ð¸ÐºÐ°ÑÐ¸Ð²Ð½ÑÑ ÑÐ²Ð¾Ð¹ÑÑÐ² Ð½Ð¾Ð²Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð±ÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾ Ð¾ÑÑÑÑÑÑÐ²Ð¸Ðµ Ð½ÐµÐ³Ð°ÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ Ð´Ð¾Ð¿Ð¾Ð»Ð½Ð¸ÑÐµÐ»ÑÐ½Ð¾Ð¹ Ð²ÑÑÐ°Ð²ÐºÐ¸ M2e Ð½Ð° ÑÐµÐ¿Ð»Ð¸ÐºÐ°ÑÐ¸Ð²Ð½ÑÐµ ÑÐ²Ð¾Ð¹ÑÑÐ²Ð° Ð²Ð¸ÑÑÑÐ° Ð¿Ð¾ ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ñ Ñ Ð½ÐµÐ¼Ð¾Ð´Ð¸ÑÐ¸ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÐ¼ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÐµÐ¼. ÐÐ´Ð½Ð°ÐºÐ¾, Ð±ÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ Ð² ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ñ Ð´Ð²ÑÐºÑÐ°ÑÐ½Ð¾Ð¹ Ð¸Ð½ÑÑÐ°Ð½Ð°Ð·Ð°Ð»ÑÐ½Ð¾Ð¹ Ð¸Ð¼Ð¼ÑÐ½Ð¸Ð·Ð°ÑÐ¸Ð¸ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÐ¹ Ð²Ð°ÐºÑÐ¸Ð½Ð½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ ÑÑÐ¸Ð¼ÑÐ»Ð¸ÑÑÐµÑ Ð´Ð¾Ð¿Ð¾Ð»Ð½Ð¸ÑÐµÐ»ÑÐ½ÑÐµ M2e-ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ðµ IgG Ð°Ð½ÑÐ¸ÑÐµÐ»Ð°. Ð Ð±ÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾ ÑÑÐ¸Ð»ÐµÐ½Ð¸Ðµ Ð·Ð°ÑÐ¸ÑÐ½Ð¾Ð¹ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½Ð¾Ð³Ð¾ Ð²Ð°ÐºÑÐ¸Ð½Ð½Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð¿Ð¾ ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ñ Ñ ÐºÐ»Ð°ÑÑÐ¸ÑÐµÑÐºÐ¸Ð¼ Ð²Ð°ÐºÑÐ¸Ð½Ð½ÑÐ¼ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÐµÐ¼. Ð Ð°Ð±Ð¾ÑÐ° Ð²ÑÐ¿Ð¾Ð»Ð½ÐµÐ½Ð° Ð² Ð»Ð°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ¸Ð¸ Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¸ Ð¿ÑÐ¾ÑÐ¸Ð»Ð°ÐºÑÐ¸ÐºÐ¸ Ð²Ð¸ÑÑÑÐ½ÑÑ Ð¸Ð½ÑÐµÐºÑÐ¸Ð¹ Ð¾ÑÐ´ÐµÐ»Ð° Ð²Ð¸ÑÑÑÐ¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¸Ð¼. Ð.Ð. Ð¡Ð¼Ð¾ÑÐ¾Ð´Ð¸Ð½ÑÐµÐ²Ð° Ð¤ÐµÐ´ÐµÑÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ ÐÐ¾ÑÑÐ´Ð°ÑÑÑÐ²ÐµÐ½Ð½Ð¾Ð³Ð¾ ÐÑÐ´Ð¶ÐµÑÐ½Ð¾Ð³Ð¾ ÐÐ°ÑÑÐ½Ð¾Ð³Ð¾ Ð£ÑÑÐµÐ¶Ð´ÐµÐ½Ð¸Ñ ÐÐ½ÑÑÐ¸ÑÑÑÐ° Ð­ÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½Ð¾Ð¹ Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½Ñ (Ð¤ÐÐÐÐ£ Â«ÐÐ­ÐÂ»).
description: The circulation of influenza viruses among animals and humans is still a significant health problem. The main means of combating this type of virus is vaccination. But current vaccines often have low efficacy. Therefore, vaccines that would have a wider and longer spectrum of action are being developed all over the world. One of the approaches to creating such vaccines is the induction of an enhanced immune response to conservative sites of the influenza virus, such as the extracellular domain of the membrane protein M2 (M2e). In this work, the M2e fragment was embedded into the Sb epitope of the globular domain of the hemagglutinin (HA) surface protein by reverse genetics methods. And then the corresponding recombinant vaccine strain was obtained based on the attenuation donor A/Leningrad/134/17/57 . As a result of studying the replicative properties of the new strain, it was shown that the additional M2e insertion had no negative effect on the replicative properties of the virus compared to the unmodified control. However, it has been shown that as a result of double intranasal immunization, the recombinant vaccine strain stimulates additional M2e-specific IgG antibodies. And it was shown to enhance the protective effectiveness of the recombinant vaccine strain compared to the classical vaccine control. The work was performed in the Laboratory of Immunology and Prevention of Viral Infections of the Department of Virology named after A.A. Smorodintsev of the Federal State Budgetary Scientific Institution of the Institute of Experimental Medicine.